CAG
ABBV icon

Centerpoint Advisory Group’s AbbVie ABBV Stock Holding History

Centerpoint Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Sell
5,772
-215
-4% -$46.3K 0.92% 31
2026
Q1 		$1.3M Hold
5,987
– – 0.98% 30
2025
Q4 		$1.37M Sell
5,987
-350
-6% -$79.7K 1.05% 27
2025
Q3 		$1.47M Sell
6,337
-3
-0% -$611 1.14% 23
2025
Q2 		$1.18M Buy
6,340
+300
+5% +$55.8K 1.02% 25
2025
Q1 		$1.27M Sell
6,040
-86
-1% -$16.7K 1.24% 23
2024
Q4 		$1.09M Buy
+6,126
New +$1.13M 1.05% 29

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Centerpoint Advisory Group's ABBV Position: Q2 2026 in Review

Centerpoint Advisory Group reduced its AbbVie (ABBV) stake by 3.6% in Q2 2026, selling an estimated $46.3K and leaving 5,772 shares worth $1.45M. The position accounts for 0.92% of the portfolio, ranked #31.

Centerpoint Advisory Group first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.47M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Centerpoint Advisory Group held 5,772 shares of AbbVie worth $1.45M as of Q2 2026.
  • Centerpoint Advisory Group sold 215 AbbVie shares in Q2 2026, an estimated $46.3K.
  • AbbVie made up 0.92% of Centerpoint Advisory Group's portfolio in Q2 2026, its #31 holding.
  • Centerpoint Advisory Group first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Centerpoint Advisory Group's AbbVie position peaked at $1.47M in Q3 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Centerpoint Advisory Group's 13F filing for Q2 2026, filed 29 Jul 2026.